- Abstract:
-
Previous preclinical research has shown that extracorporeal devices can be used to enhance the delivery and distribution of systemically administered anticancer drugs, resulting in increased intratumoural concentrations. We aimed to assess the safety and feasibility of targeted release and enhanced delivery of doxorubicin to solid tumours from thermosensitive liposomes triggered by mild hyperthermia, induced non-invasively by focused ultrasound.We did an open-label, single-centre, phase 1 tri...
Expand abstract - Publication status:
- Published
- Peer review status:
- Peer reviewed
- Version:
- Publisher's version
- Publisher:
- Elsevier Publisher's website
- Journal:
- Lancet Oncology Journal website
- Volume:
- 19
- Issue:
- 8
- Pages:
- 1027-1039
- Publication date:
- 2018-07-11
- Acceptance date:
- 2018-04-20
- DOI:
- EISSN:
-
1470-2045
- ISSN:
-
1474-5488
- Pubs id:
-
pubs:889877
- URN:
-
uri:114c2816-9ca6-49a3-aeea-003f942e8ac1
- UUID:
-
uuid:114c2816-9ca6-49a3-aeea-003f942e8ac1
- Local pid:
- pubs:889877
- Language:
- English
- Keywords:
- Copyright holder:
- © 2018 Lyon, et al. Published by Elsevier Ltd.
- Copyright date:
- 2018
- Notes:
- This is an Open Access article under the CC BY license
Journal article
Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trial
Actions
Authors
Funding
National Institute for Health Research
More from this funder
Bibliographic Details
Item Description
Terms of use
Metrics
Altmetrics
Dimensions
If you are the owner of this record, you can report an update to it here: Report update to this record